Showing 8691-8700 of 18582 results for "".
- Study Finds Cardiovascular Disease Risk Can Develop Decades Earlier in People with Diabetes and Kidney Diseasehttps://reachmd.com/news/study-finds-cardiovascular-disease-risk-can-develop-decades-earlier-in-people-with-diabetes-and-kidney-disease/2468620/New research presented at the American Heart Association’s Scientific Sessions 2024 has revealed a troubling link between cardiovascular-kidney-metabolic (CKM) syndrome and early cardiovascular disease (CVD) risk. CKM syndrome—a condition characterized by the connections between cardiovascular di
- Want to Prevent Diabetes? Stop Eating So Much of This One Food, Harvard Experts Sayhttps://reachmd.com/news/want-to-prevent-diabetes-stop-eating-so-much-of-this-one-food-harvard-experts-say/2467780/Burger lovers may flip out over this news. A new Harvard study establishes a “significant” link between a key component in
- Diabetes and Obesity Can Damage the Liver to the Point of Failure – But Few People Know Their Risk of Developing Liver Diseasehttps://reachmd.com/news/diabetes-and-obesity-can-damage-the-liver-to-the-point-of-failure-but-few-people-know-their-risk-of-developing-liver-disease/2467588/Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Fo
- Researchers Find GLP-1 Medications Safe to Continue Before Surgery in Patients with Diabetes and Obesityhttps://reachmd.com/news/researchers-find-glp-1-medications-safe-to-continue-before-surgery-in-patients-with-diabetes-and-obesity/2466941/Credit: American Journal of Gastroenterology (2024). DOI: 10.14309/ajg.0000000000002820 In a meta-analysis and review
- Breaking Down the TUXEDO-2 Findings: Antithrombotic Choices After PCIhttps://reachmd.com/news/breaking-down-the-tuxedo-2-findings-antithrombotic-choices-after-pci/2484417/TUXEDO-2 shows prasugrel reduced one‑year ischemic events and major bleeding compared with ticagrelor in patients with diabetes undergoing drug‑eluting stent placement — a finding that should influence P2Y12 selection for high‑risk diabetic PCI patients. In a randomi
- FDA's Regulatory Green Light for Gene-Editing Therapy in PH1 Spurs New Hope in Renal Disease Treatmenthttps://reachmd.com/news/fdas-regulatory-green-light-for-gene-editing-therapy-in-ph1-spurs-new-hope-in-renal-disease-treatment/2484579/The FDA has cleared the YOLT-203 pivotal trial, enabling a first‑in‑class in vivo gene‑editing pivotal study for Primary Hyperoxaluria Type 1 (PH1).
- Emergency Departments Frequently Miss Signs of Epilepsy in Childrenhttps://reachmd.com/news/emergency-departments-frequently-miss-signs-of-epilepsy-in-children/2462931/A subtle type of seizure goes undetected two-thirds of the time in pediatric emergency departments, a new study shows. The work focuses on “nonm
- Transforming Cancer Screening: The Potential of the Galleri Blood Testhttps://reachmd.com/news/transforming-cancer-screening-the-potential-of-the-galleri-blood-test/2484016/A single ctDNA blood test now demonstrates multi-cancer detection capability with a high specificity and a majority of detections at stage I–II, expanding early-stage identification beyond current single-organ screens. This was determined by the
- Emerging Therapies in Proteinuria: Pegcetacoplan and Atrasentan Lead the Chargehttps://reachmd.com/news/emerging-therapies-in-proteinuria-pegcetacoplan-and-atrasentan-lead-the-charge/2475642/Persistent proteinuria and progressive loss of renal function in disorders like C3 glomerulopathy and immune-complex–mediated membranoproliferative glomerulonephritis represent a critical blind spot in nephrology, yet the clinical landscape i
- Study Highlights Role of Patient-Reported Outcomes in Botulinum Toxin Developmenthttps://reachmd.com/news/study-highlights-role-of-patient-reported-outcomes-in-botulinum-toxin-development/2475414/A patient-centric clinical approach, driven by the evolution of patient-reported outcomes (PROs), has been central to the development of onabotulinumtoxinA for aesthetic indications, according to new research in the Journal of Cosmetic Dermatology. Researchers concluded there is i